Swiss Biotech Stock News

SWX:SIKA
SWX:SIKAChemicals

Assessing Sika (SWX:SIKA) Valuation After 2026 Earnings Guidance Confirmation

Guidance confirmation puts Sika (SWX:SIKA) back in focus Sika (SWX:SIKA) has drawn fresh attention after management reiterated 2026 earnings guidance, signaling an expectation for 1% to 4% sales growth in local currencies and a continued aim to outperform its reference market, including bolt-on acquisitions. See our latest analysis for Sika. The guidance confirmation comes after a sharp short term rebound, with a 7 day share price return of 9.06% and a 30 day share price return of 11.14%,...
SWX:SCHN
SWX:SCHNMachinery

Schindler Holding (SWX:SCHN) Valuation Check As Goldman Sachs Upgrade Highlights Shifting Growth Drivers

Goldman Sachs has revised its view on Schindler Holding (SWX:SCHN), upgrading the stock to a neutral rating from sell. The firm cited factors such as backlog conversion, modernization activity and reduced exposure to China as key reasons for the reassessment. See our latest analysis for Schindler Holding. At a share price of CHF261.0, Schindler Holding has seen a 7 day share price return of 2.55% but a 90 day share price return decline of 10.77%, while the 3 year total shareholder return of...
SWX:UBSG
SWX:UBSGCapital Markets

UBS Ruling Clears Key Legal Risk As Investors Reassess Valuation And Momentum

Switzerland’s Federal Criminal Court has cleared UBS Group of liability in the Mozambique tuna bond money laundering case. The decision relates to alleged misconduct tied to Credit Suisse, which UBS acquired in 2023. The ruling removes a major legal overhang linked to pre acquisition Credit Suisse activities for UBS Group. For investors tracking SWX:UBSG, this court decision lands at a time when the stock is trading at CHF33.48 and has shown strong longer term share price gains, with a...
SWX:ROP
SWX:ROPPharmaceuticals

Roche Holding (SWX:ROP) Valuation Check After Mixed Short Term Share Performance

Roche Holding: recent share performance and business profile Roche Holding (SWX:ROP) has drawn investor interest after a mixed share performance, with a small move higher over the past week set against negative returns over the past month and past 3 months. At a last close of CHF 318.10, Roche sits within the large cap pharmaceuticals and diagnostics group, with a market value of roughly CHF 254.2b and operations spanning Europe, North America, Latin America, Asia, Africa, Australia and New...
SWX:ABBN
SWX:ABBNElectrical

ABB’s Synchronous Condenser Role Meets Questions On Valuation And Insider Selling

ABB (SWX:ABBN) is featured as a major supplier of synchronous condensers as global grid operators invest in equipment to support renewable energy integration. The company is highlighted for coupling these large rotating machines with digital monitoring and control tools for grid stability projects. Growing interest in grid modernization gives ABB additional visibility in a niche segment of transmission infrastructure. For you as an investor, this centers ABB around a key piece of hardware...
SWX:COPN
SWX:COPNPharmaceuticals

Does Cosmo Pharmaceuticals' (SWX:COPN) New €2.10 Dividend Clarify Its Capital Allocation Priorities?

Cosmo Pharmaceuticals N.V. reported that shareholders at its recent Ordinary AGM approved all proposals, including a €2.10 per share dividend, with the ex-dividend date set for 24 April 2026 and payment on 11 May 2026. This broad shareholder backing for both governance items and a cash distribution highlights confidence in the company’s capital allocation approach and cash-generating capacity. We’ll now examine how this newly approved €2.10 dividend and strong shareholder support feed into...
SWX:BRKN
SWX:BRKNConstruction

Burkhalter Holding (SWX:BRKN) Margin Uptick To 5.1% Tests Concerns Over Slowing Earnings Growth

Burkhalter Holding (SWX:BRKN) has opened FY 2025 with first half revenue of CHF 559.0 million and basic EPS of CHF 2.26, providing a new set of figures for investors to compare with its recent track record. Over the past few reporting periods, revenue changed from CHF 526.9 million and EPS of CHF 2.19 in 1H 2024 to CHF 629.7 million and EPS of CHF 3.20 in 2H 2024. Trailing 12 month EPS was most recently CHF 5.78 on revenue of about CHF 1.2b, giving context to a business where profitability...
SWX:RSGN
SWX:RSGNElectrical

R&S Group Holding (SWX:RSGN) Is Up 24.9% After Strong 2025 Earnings Beat Has The Bull Case Changed?

R&S Group Holding AG recently reported its full-year 2025 results, with sales rising to CHF 414.84 million and net income reaching CHF 58.1 million, both higher than the prior year. The improvement in basic earnings per share from continuing operations to CHF 1.56 highlights enhanced profitability on a per-share basis alongside the company’s broader growth. With this earnings-driven backdrop and stronger per-share profitability, we will explore how these results shape R&S Group Holding’s...
SWX:ROG
SWX:ROGPharmaceuticals

How Investors Are Reacting To Roche Holding (SWX:ROG) CE Mark For Elecsys NfL MS Blood Test

In early April 2026, Roche announced that its Elecsys Neurofilament Light Chain (NfL) blood test received CE mark approval for detecting neuroinflammation in adults with relapsing-remitting multiple sclerosis, enabling minimally invasive monitoring via its widely installed cobas instruments. This approval could materially change multiple sclerosis care pathways by shifting more frequent disease monitoring from hospital-based MRI scans to accessible, standardized blood testing. Next, we’ll...
SWX:SENS
SWX:SENSElectronic

Assessing Sensirion Holding’s Valuation As AI Sensor Demand And Sustainability Progress Draw Investor Interest

Sensirion Holding (SWX:SENS) is back in focus after partnering with ClimeFi to secure durable carbon removal solutions through 2028. This reinforces its net zero roadmap while interest in its AI related sensor business stays in view. See our latest analysis for Sensirion Holding. The latest moves come against a backdrop of improving momentum, with a 1 month share price return of 10.65% and a 1 year total shareholder return of 11.42%, even though the 3 year total shareholder return is a 32.85%...
SWX:IDIA
SWX:IDIABiotechs

Assessing Idorsia (SWX:IDIA) Valuation After Positive Pediatric Insomnia Results For Daridorexant

Idorsia’s pediatric insomnia data puts daridorexant in the spotlight Idorsia (SWX:IDIA) is back on investors’ radar after reporting statistically significant, dose dependent improvements in sleep time for children with insomnia treated with daridorexant, confirming safety and efficacy in patients as young as ten. See our latest analysis for Idorsia. Despite the positive pediatric insomnia data and the recent leadership change in clinical development, Idorsia’s CHF3.524 share price reflects...
SWX:AMS
SWX:AMSSemiconductor

ams-OSRAM (SWX:AMS) Is Up 22.0% After AI Sensor Demand Lifts Margins And Orders - What's Changed

Earlier in April 2026, ams-OSRAM reported stronger-than-expected trading, underpinned by improving margins and increased orders for its optical sensor portfolio in automotive and AI applications. The news highlighted how renewed demand for AI-related optical sensors is starting to influence perceptions of ams-OSRAM’s operational progress despite ongoing balance sheet and profitability challenges. We’ll now examine how this renewed interest in AI-related optical sensors could shape...
SWX:SDZ
SWX:SDZPharmaceuticals

Sandoz AGM Backing Underscores Valuation Gap And Share Price Momentum

Sandoz Group shareholders approved all proposals at the 2026 AGM, including board re elections and governance roles. Compensation plans for leadership and a dividend payment were endorsed, confirming broad investor backing. The AGM outcome points to continuity in how Sandoz Group is run and how its strategy is overseen. Sandoz Group (SWX:SDZ) held this AGM with the share price at CHF66.62 and a 1 year return of 114.0%. The stock has also posted returns of 4.1% over the past week, 7.6% over...
SWX:HOLN
SWX:HOLNBasic Materials

Is Holcim (SWX:HOLN) Quietly Repositioning Its Margin Profile Through Electrified Cement Production?

SaltX recently reported that it has completed the first industrial-scale test period of electrified precalcination of Holcim’s cement raw meal at its ECRC facility in Hofors, Sweden, achieving positive calcination results and operational stability while processing around 20 tonnes per test run. This progress, alongside parallel work on electrified sintering and a fully electrified pilot plant targeted for 2028, highlights Holcim’s push to electrify and decarbonize cement production at an...
SWX:RSGN
SWX:RSGNElectrical

Assessing R&S Group Holding (SWX:RSGN) Valuation After Full Year 2025 Results Attract Investor Interest

Earnings highlight and why it matters now R&S Group Holding (SWX:RSGN) just released its full year 2025 results, with sales of CHF 414.84 million, revenue of CHF 417.53 million, and net income of CHF 58.1 million drawing fresh attention to the stock. See our latest analysis for R&S Group Holding. The latest results appear to have kept momentum strong, with the share price at CHF24.2 and a 7 day share price return of 22.84% building on a 90 day share price return of 55.33%. The 3 year total...
SWX:BAER
SWX:BAERCapital Markets

Julius Baer Gruppe (SWX:BAER) Valuation Check As Leadership Changes Reshape Investor Expectations

Julius Bär Gruppe (SWX:BAER) is in the spotlight after a series of leadership changes, including the planned departure of finance chief Evie Kostakis and new board responsibilities for incoming non executive director Colin Bell. See our latest analysis for Julius Bär Gruppe. The executive reshuffle comes as the stock shows mixed momentum, with a 4.9% 1 month share price return and a 1 year total shareholder return of 33.7% contrasting with weaker recent quarterly performance. If leadership...
SWX:MOVE
SWX:MOVEMedical Equipment

Assessing Medacta Group’s Valuation After Its T Rex Hip Implant Revival Project Announcement

Medacta Group (SWX:MOVE) has stepped into an unusual spotlight after being selected to engineer a load bearing hip implant for a resurrected Tyrannosaurus rex as part of an international dinosaur revival project. See our latest analysis for Medacta Group. While the dinosaur project has put Medacta in the headlines, the CHF153.4 share price sits below its recent peak, with short term share price returns weaker. However, a 1 year total shareholder return of 34.52% still points to solid long...
SWX:AVOL
SWX:AVOLSpecialty Retail

A Look At Avolta (SWX:AVOL) Valuation After New 15 Year Jacksonville Airport Contract

Avolta (SWX:AVOL) has secured a 15 year food and beverage contract at Jacksonville International Airport in Florida, adding a new airport food hall with four outlets that mix local concepts and national brands. See our latest analysis for Avolta. The Jacksonville contract lands at a time when Avolta’s share price sits at CHF52.2, with a 1 month share price return of 8.70% and a 1 year total shareholder return of 57.10%. This suggests momentum has been building recently despite a weaker 5 year...